<DOC>
	<DOCNO>NCT00010192</DOCNO>
	<brief_summary>Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining rituximab interleukin-2 may kill cancer cell . Phase I trial study effectiveness rituximab plus interleukin-2 treating patient hematologic cancer .</brief_summary>
	<brief_title>Rituximab Plus Interleukin-2 Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Determine dose-limiting toxicity rituximab follow low-dose intermediate-dose pulse interleukin-2 ( IL-2 ) patient CD20-positive B-cell lymphoid malignancy . Determine maximum tolerate dose intermediate-dose pulse IL-2 patient population . Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study intermediate-dose pulse aldesleukin . Patients receive rituximab IV day 1 , 8 , 15 , 22 . Patients receive low-dose aldesleukin subcutaneously ( SC ) day 29-39 , 43-53 , 57-67 , 71-81 , intermediate-dose aldesleukin SC day 40-42 , 54-56 , 68-70 , 82-84 . Cohorts 3-6 patient receive escalate dos intermediate-dose pulse aldesleukin maximum tolerate dose ( MTD ) reach . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 3-30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologically immunophenotypically proven CD20positive Bcell lymphoproliferative disorder Recurrent progressive lowgrade Bcell lymphoma least one prior chemotherapy regimen ( may include monoclonal antibody ) Relapsed intermediategrade highgrade Bcell lymphoma Blineage acute lymphoblastic leukemia patient candidate , refuse , fail prior hematopoietic stem cell transplantation No chronic lymphocytic leukemia lymphoma 5,000/mm3circulating lymphoma cell Measurable evaluable disease Must fail standard curative therapy No CNS leptomeningeal metastasis Performance status Karnofsky 70100 % Performance status ECOG 01 At least 4 month Absolute neutrophil count least 1,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) Platelet count least 50,000/mm^3 AST great upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Hepatitis B surface antigen negative Creatinine great ULN No prior unstable coronary artery disease No New York Heart Association class III IV congestive heart failure DLCO FEV1 least 50 % predict HIV negative No concurrent malignancy except nonmelanoma skin cancer carcinoma situ cervix No infection require IV antibiotic therapy within past 4 week No major illness would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception See Disease Characteristics Prior antibody therapy allow Prior interleukin2 interferon alfa allow See Disease Characteristics At least 4 week since prior chemotherapy At least 4 week since prior systemic corticosteroid At least 4 week since prior radiotherapy At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>